Capmatinib | B3005

Capmatinib is an ATP competitive inhibitor of c-MET kinase or hepatocyte growth factor receptor (HGFR). Binding of Hepatocyt Growth Factor to c-MET receptor causes activation of multiple downstream pathways. Capmatinib potently inhibits in vitro kinase activity with an IC₅₀ of 0.13 nM. It prevents HGF-stimulated H441 cell migration with an IC₅₀ value of a ~2 nM. It inhibts c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.

Capmatinib is an ATP competitive inhibitor of c-MET kinase or hepatocyte growth factor receptor (HGFR). Binding of Hepatocyt Growth Factor to c-MET receptor causes activation of multiple downstream pathways. Capmatinib potently inhibits in vitro kinase activity with an IC₅₀ of 0.13 nM. It prevents HGF-stimulated H441 cell migration with an IC₅₀ value of a ~2 nM. It inhibts c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.

B3005 | Capmatinib DataSheet

Alternate Name/Synonyms: INC280; INCB28060; INC28060; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide

Appearance: Yellow solid powder

Formulation:

CAS Number: 1029712-80-8

Structure Available?: TRUE

Peptide sequence:

Salt Form: FALSE

Molecular Formula: C₂₃H₁₇FN₆O

Molecular Weight: 412.4

Cell-Permeable?: FALSE

Purity: >98%

Solubilities: ~0.3 mg/ml in DMSO, ~1 mg/ml in DMF

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: An ATP competitive inhibitor of c-MET kinase

MDL Number: MFCD18633285

PubChem CID: 25145656

SMILES: CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F

InChi: InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

InChi Key: LIOLIMKSCNQPLV-UHFFFAOYSA-N